-+ 0.00%
-+ 0.00%
-+ 0.00%

Compass Therapeutics Q1 net loss widens to $18.3 million; G&A expenses climb 41% to $6.9 million

PUBT·05/05/2026 11:30:38
Listen to the news
Compass Therapeutics Q1 net loss widens to $18.3 million; G&A expenses climb 41% to $6.9 million
  • Compass Therapeutics posted a Q1 net loss of USD 18.3 million, widening from USD 16.6 million; loss per share narrowed to USD 0.10 from USD 0.12.
  • R&D expenses inched up 3% to USD 13.4 million, while G&A costs jumped 41% to USD 6.9 million on pre-commercialization spending of USD 1 million and higher stock compensation.
  • Cash and marketable securities fell to USD 195 million from USD 209 million at year-end, with management projecting runway into 2028.
  • Tovecimig plus paclitaxel delivered a 17.1% overall response rate versus 5.3% for paclitaxel alone in Phase 2/3 biliary tract cancer, with progression-free survival improving to 4.7 months from 2.6 months (HR=0.44, p<0.0001).
  • Orphan Drug Designation for tovecimig was granted in April; Compass plans an FDA meeting ahead of a planned BLA filing later this year, while CTX-8371 Phase 1 data will be presented at ASCO 2026 and CTX-10726 initial data are expected in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605050730PRIMZONEFULLFEED9712623) on May 05, 2026, and is solely responsible for the information contained therein.